Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyoscine butylbromide is an anticholinergic and antispasmodic pharmaceutical drug used to relieve pain and discomfort caused by smooth muscle spasms in the gastrointestinal tract, urinary tract, and other organs. It works primarily as a competitive antagonist at muscarinic acetylcholine receptors, leading to relaxation of smooth muscle. This action helps alleviate abdominal pain associated with conditions such as irritable bowel syndrome, diverticular disease, esophageal spasms, bladder spasms, biliary colic, and renal colic. It is also used to reduce excessive respiratory secretions at the end of life. The drug can be administered orally (tablets), rectally (suppositories), or by injection (intramuscular or intravenous)[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyoscine butylbromide.